Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.
暂无分享，去创建一个
M. Morris | A. Armstrong | C. Higano | A. Alva | D. Petrylak | L. Appleman | L. Fong | U. Vaishampayan | K. Yuen | E. Kadel | L. Pagliaro | W. Tan | A. Sartor | D. Tayama | Asim Datye | Raphaelle Porcu | Kobe Yuen